Raising a Series B or later in healthtech.
Later rounds fund scale: more buyer types, more states, more products. Investors check that sales get faster and margins hold as you grow.
Healthtech
Healthtech investors look past the demo to three questions: who pays, what evidence proves it works, and whether you can handle patient data safely. Long sales cycles shape every round.
What later-stage investors expect in healthtech
By Series B the conversation is about efficiency and reach.
A sales engine that speeds up
- Shorter sales cycles than a year ago
- Reference customers that win you the next deal
- Revenue that grows inside existing accounts
A second buyer or product
- A move from providers to payers, or the reverse
- A new product sold to existing customers
- State licensing or coverage for new markets
Margins that survive services
- Gross margin after clinical staff and support
- Less custom integration work per customer
- Reimbursement that is stable, not one-off
How the round comes together
Later healthtech rounds are led by larger venture and growth funds with health care teams.
- 1 · A larger fund leads
- 2 · Insiders follow
- 3 · Strategics and families
Multi-stage VCs
Often leads
Large venture funds with health practices lead most Series B and C rounds.
Corporate VCs
Sometimes
Payers, health systems and pharma invest to secure distribution.
Family offices
Sometimes
Families take larger positions once contracts are proven.
Pre-seed & seed funds
Now and then
Early investors may keep a small pro-rata.
Preferences start to matter
Later rounds bring larger checks and more negotiated terms. Liquidation preferences decide who gets paid first in an exit, and health care exits are often sales to strategics. Model the waterfall.
The slides investors read first
Efficiency
Sales cycle, payback and net retention.
Expansion
The next buyer type or product, with proof.
Outcomes
Results at scale, across many customers.
Margins
What you keep after clinical and support costs.
The plan
What the round buys and the path to profit.
Questions founders ask
Do later-stage healthtech investors care about profit?
More than before. Expect questions on gross margin after clinical staff, how much burn each new contract costs and when the business pays for itself.
How do reimbursement changes affect a Series B?
Investors will test how exposed you are to a single payment rule or code. Show revenue from more than one payment source if you can.
Sources
Sources: HHS guidance on HIPAA; FDA guidance on digital health software; CMS reimbursement resources; investors' published criteria. Editorial content, reviewed quarterly. Not financial, legal or medical advice.
Other stages
Related sectors
Who funds this round
Learn the terms
Run the numbers
Raise in your city
Inside Unicorn Factory
Free account
Investor matching is coming to your free account. Create it now and we will match your round the day it opens. Until then, get an honest read on your deck.